Jaafer Golzar, MD
Interventional Cardiology · Oak Lawn, ILNPI 1073577193
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Angiodynamics, Inc. at 28.6% of the total. 2025 is the largest year on record at $55,033, more than ten times the $1,810 reported in 2019. Among interventional cardiology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 557 payments — averaging $272.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$43K
- Penumbra, Inc.$31K
- Endologix LLC$29K
- Johnson & Johnson$18K
- Boston Scientific$15K
- Cardiovascular Systems Inc.$4K
- plus $12K from 29 others
Across 58 payments — averaging $1886.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- M.a. Med Alliance S.A.$46K
- Boston Scientific$46K
- Intact Vascular, Inc.$14K
- Philips North America LLC$3K
- W. L. Gore & Associates, Inc.$300
What the payments were for
- Consulting fees$86,11057%
- Speaking & faculty fees$25,33717%
- Travel & lodging$16,53811%
- Food & beverage$23,34815%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 47 | $43,352 |
| Penumbra, Inc. | 40 | $30,532 |
| Endologix LLC | 37 | $28,721 |
| Johnson & Johnson(2 entities) | 38 | $17,998 |
| Boston Scientific | 104 | $14,976 |
| Cardiovascular Systems Inc. | 52 | $3,734 |
| Philips North America LLC | 14 | $3,644 |
| Bard Peripheral Vascular, Inc. | 29 | $1,683 |
| Abbott | 39 | $1,137 |
| Mercator Medsystems, Inc. | 3 | $1,086 |
| Avinger Inc. | 17 | $711 |
| Novo Nordisk | 16 | $640 |
| Terumo Medical Corporation | 14 | $528 |
| Esperion Therapeutics, Inc. | 17 | $352 |
| Thrombolex, Inc. | 2 | $288 |
| Tactile Systems Technology Inc | 25 | $279 |
| Janssen Scientific Affairs, LLC | 4 | $255 |
| Novartis | 11 | $216 |
| Boehringer Ingelheim | 7 | $178 |
| Amgen | 9 | $177 |
| Cook Medical LLC | 4 | $177 |
| Inari Medical, Inc. | 7 | $173 |
| Biotronik Inc. | 1 | $149 |
| Reflexion Medical, Inc. | 1 | $148 |
| Medtronic | 5 | $89 |
| Vasorum USA Inc. | 1 | $79 |
| AstraZeneca(2 entities) | 2 | $43 |
| W. L. Gore & Associates, Inc. | 2 | $36 |
| Pfizer | 2 | $35 |
| Cordis US CORP. | 2 | $33 |
| Shockwave Medical, Inc | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AlphaVac$32,225
- Indigo System$29,923
- Torus Stent Graft System$27,290
- ENDOCROSS Device$27,290
- XARELTO$17,524
- AngioVac$6,984
- GENERAL - THERAPIES$6,949
- Auryon Laser System 100-120 Vac$3,005
- Diamondback Peripheral$2,286
- (6554) Periph Vasc Undiv$1,248
- Bullfrog$1,086
- (9520) IGT Devices Undivided$1,000
- VenaCure 1470 Pro$569
- (6554) Peripheral Vascular Undivided$502
- ELUVIA$468
- GENERAL VASCULAR INTERVENTION$426
- Stellarex$372
- Bashir Endovascular Catheter$288
- Absorb GT1$275
- Peripheral Orbital Atherectomy System$250
How this compares
$151,531 in reported general payments places this provider in the 95th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 82 | $87,373 |
| XareltoRivaroxaban | 81 | $71,896 |
| NexlizetBempedoic Acid/Ezetimibe | 99 | $60,563 |
| Repatha SureclickEvolocumab | 84 | $58,224 |
| EliquisApixaban | 59 | $48,307 |
| EntrestoSacubitril/Valsartan | 26 | $27,810 |
| Repatha SyringeEvolocumab | 27 | $11,714 |
| JardianceEmpagliflozin | 11 | $8,272 |
| Rosuvastatin Calcium | 214 | $3,308 |
| ClopidogrelClopidogrel Bisulfate | 295 | $2,661 |
| Ranolazine ErRanolazine | 15 | $1,408 |
| Cilostazol | 48 | $1,376 |
| Metoprolol Succinate | 93 | $1,144 |
| Nifedipine ErNifedipine | 39 | $1,026 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 58 | $778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $640 | $87,37382 claims |
| Johnson & JohnsonXarelto | $17,998 | $71,89681 claims |
| Esperion Therapeutics, Inc.Nexlizet | $352 | $60,56399 claims |
| PfizerEliquis | $35 | $48,30759 claims |
| NovartisEntresto | $216 | $27,81026 claims |
| Boehringer IngelheimJardiance | $178 | $8,27211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Oak Lawn
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
- Sudhir MungeePeoria$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.